Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded.
Travere Therapeutics Inc. (TVTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 13,000,000 | $12,780,300 | 7.67% | ||
| 2. | 11,615,000 | $11,462,554 | -8% | 0.35% | |
| 3. | 1,377,000 | $1,351,652 | +34% | 0.03% | |
| 4. | 30,000 | $29,679 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | Officer, Director | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | Director | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | Director | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | Director | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | Officer, Director | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.05 | 1,784 | 93,126 | 2025-05-05 | Filing | ||
| $21.05 | 18,924 | 419,173 | 2025-05-05 | Filing | ||
| $21.05 | 1,771 | 128,215 | 2025-05-05 | Filing | ||
| $21.05 | 3,198 | 100,241 | 2025-05-05 | Filing | ||
| $21.05 | 4,920 | 89,482 | 2025-05-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | Css LlcBOND | 21,110,000 | $20,826,366 | 1.14% |
| 2. | 8,000 | $7,852,736 | 0.3% | |
| 3. | 1,040,000 | $1,030,294 | 0% | |
| 4. | 9,460,000 | $9,285 | 0.01% | |
| 5. | 0 | $0 | 0% |
News See All
10 Best Small-Cap Stocks to Buy Before They Explode
Since the announcement of tariffs, investors have been concerned regarding the market volatility.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. Today's call is being recorded.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript October 31, 2024Travere Therapeutics, Inc. misses on earnings expectations.
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Travere Therapeutics' Second Quarter 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript
Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.7639 EPS, expectations were $-0.98. Travere Therapeutics, Inc.
5 Best Biotech Stocks To Buy Under $20
In this article, we are going to take a closer look at five best biotech stocks to buy under $20.
5 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 5 best medical stocks to buy under $10.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.
Billionaire Hedge Funds
